Lymphangioleiomyomatosis Clinical Trial
Official title:
National Lymphangioleiomyomatosis Registry, France
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis. Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.
Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression. Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France. Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals). This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01687179 -
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
|
Phase 1 | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
Unknown status |
NCT00490789 -
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
|
Phase 2 | |
Not yet recruiting |
NCT05087134 -
Characterizing LAM With 11C-Choline PET/CT
|
Early Phase 1 | |
Completed |
NCT02009241 -
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
|
N/A | |
Recruiting |
NCT05190627 -
Effect of Loratadine in Lymphangioleiomyomatosis
|
Phase 2 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Completed |
NCT02859194 -
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
|
N/A | |
Completed |
NCT01353209 -
Letrozole for Lymphangioleiomyomatosis
|
Phase 2 | |
Completed |
NCT03253913 -
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
|
Phase 2 | |
Recruiting |
NCT02432560 -
Safety and Durability of Sirolimus for Treatment of LAM
|
||
Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Recruiting |
NCT04577937 -
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
|
N/A | |
Completed |
NCT00005906 -
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
|
Phase 2 | |
Recruiting |
NCT01799538 -
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|
||
Enrolling by invitation |
NCT05727852 -
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
|